Alector ALEC 深 滬
交易中 04-01 11:53:47 美东时间
2.495
+0.345
+16.05%
華盛通- 最 高2.53
- 今 開2.18
- 成交量 75.86万股
- 最 低 2.175
- 昨 收 2.15
- 總市值 2.75亿
- 52周最高 3.3999
- 市盈率 靜 --
- 換手率 0.69%
- 52周最低 0.904
- 委 比 6.18%
- 總股本 1.10亿
- 歷史最高 43.32
- 量 比 5.32
- 振 幅 16.51%
- 歷史最低 0.87
- 每 手 1
- 風險率 0.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Wall Street analysts upgraded CRWD, ALEC, RIVN, SEDG, and DNTH. See what other analysts say about these stocks. Consider buying CRWD.
03-10 20:32
BTIG Upgrades Alector to Buy, Announces $6 Price Target
BTIG analyst Thomas Shrader upgrades Alector (NASDAQ:ALEC) from Neutral to Buy and announces $6 price target.
03-10 18:18
Alector Q4 Earnings Assessment
The Q4 earnings report for Alector (NASDAQ:ALEC) was released on Wednesday, Feb...
02-26 05:48
Alector Q4 EPS $(0.34) Beats $(0.39) Estimate, Sales $6.237M Beat $2.672M Estimate
Alector (NASDAQ:ALEC) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 13.71 percent. This is a 1600 percent decrease over losses of $(0.02) per share from the same
02-26 05:47
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Alector reported fourth quarter and full year 2025 financial results and updates, highlighting progress across its pipeline of neurodegenerative disease therapies. The company's cash, cash equivalents, and investments totaled $256.0 million as of December 31, 2025, providing runway through 2027. Key updates include advancements in the Alector Brain Carrier (ABC) platform for antibodies, enzymes, and siRNA, IND-enabling studies for AL137 (anti-amy...
02-25 21:05
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
<p>Alector, a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. A live webcast and replay of the presentation will be available on Alector's investor website. The company specializes in combating neurodegeneration through innovative approaches, including removing toxic proteins and enhancing therapeutic delivery wit...
02-24 13:00
Alector Ends Latozinemab Continuation Study: Reading the Signals for ALEC Investors
Alector ($ALEC) announced an update on their ongoing clinical study. Alector’s ...
01-22 00:31
